MATERIALS AND METHODS

Patient characteristics.
All consecutive patients aged <40 years with acute leukemia in the first or second remission (CR) or chronic myeloid leukemia (CML) in the first chronic phase (CP) or accelerated phase (AP) were included in this study (Table I) were of different sex, the sex chromosome constitution was used to distinguish between donor and recipient 6 months after transplantation.
In the remaining cases, banding polymorphism studies were performed before BMT; in all cases, sufficient differences were found to permit recognition of the origin of the cells after BMT. MTX was used as routine GVHD prophylaxis for I 02 days in nine patients as in the Seattle regimen6 (Table   2 ).
Since GVHD did not develop in the first five patients, we attempted to omit immunoprophylaxis postgrafting in two patients. Acute GVHD developed in both (see Results), and therefore we Bone marrow was harvested from the donors as previously described.'5 A mononuclear cell fraction with a density < 1 .070 g/mL was prepared in gradients (Percoll, Uppsala, Sweden), as previously described, but the number of gradients was reduced to 12 by using 250-mL bottles (this will be described in a separate paper 
